Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.
about
Phosphodiesterase 5 inhibitors for pulmonary hypertensionNO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialInhaled therapy for the management of perioperative pulmonary hypertensionTreatment-related biomarkers in pulmonary hypertensionInhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertensionPretreatment of sildenafil attenuates ischemia-reperfusion renal injury in ratsSildenafil for pulmonary hypertension.Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitalsPivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Nitric oxide signalling and neuronal nitric oxide synthase in the heart under stress.Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension.Sildenafil reduces insulin-resistance in human endothelial cellsThe emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesUpdate on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Are hemodynamics surrogate end points in pulmonary arterial hypertension?Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and managementSildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesNon-congenital heart disease associated pediatric pulmonary arterial hypertensionDiagnosis and management of pulmonary arterial hypertensionSevere paediatric pulmonary hypertension: new management strategiesPulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.Platelets, atherosclerosis and the endothelium: new therapeutic targets?Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.Progress in the understanding and management of pulmonary arterial hypertension.Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension.Sildenafil in the treatment of pulmonary hypertension.Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Sildenafil for pulmonary arterial hypertension: when blue turns into white.Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.Current therapies for pulmonary arterial hypertension.Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design).
P2860
Q24245844-0A44245D-45E2-4CE3-9917-27B5FD6871F5Q24656131-DA9779A2-716E-4D88-A495-96847A598F54Q27026522-0A76857B-758C-49AA-AB0B-1E1CA1620681Q28081276-FC9EC972-27C8-4636-8B8C-D680B764E4C4Q28566149-25F1CC33-40C4-4C4C-B9CB-2CB18059D699Q28581703-BDA0E036-99AD-48C6-B506-753E22ED9007Q33213984-A4A37B0B-84FD-4877-8F7B-408BF46ADCCCQ33417824-5C30F4C2-0721-4120-A19E-B1BA6F4D138BQ33552229-3D1E6D1D-393F-4C90-A61E-82B39E20A8BAQ33777846-BBEC21FE-5A23-4674-8400-88A0ACD62A4BQ33788510-967B5B08-748C-420D-9852-D234512CCE38Q33813006-286CFFB9-B18F-4F8A-8A39-FCDED08DAFC0Q33844740-AEB557EC-0B14-4E9A-9192-9EB88F12C241Q33849207-78387646-9CCF-4D24-A51F-187C10AC364EQ33892575-44DCC6F5-4D04-4506-86D0-62804076C99FQ33965898-8DBE742A-7696-46C5-BA53-E39C23C334BDQ34098418-07FC844C-B53C-4462-8ABD-04F2CE1A221BQ34525179-DEB4EEDB-FD74-4DEA-8542-9B909397F940Q34558395-7CEC129B-0B8A-4071-8627-3BE6300C9FCAQ35049122-37E14FD0-E260-47EA-B3D5-161FFD548E74Q35156618-B657CA57-DA5D-47C2-BE8B-8E379176C760Q35165691-8A295314-56C8-4EC2-912D-2666A03AC067Q35222937-E3C4C76E-BDA4-4F72-A81F-22C68AFF04D5Q35280612-0F7B8E94-510D-436A-8F02-6601B937E0D4Q35559191-2D1A5A31-54A2-4A62-BD79-F5129BC45E52Q35570940-CE3DA25B-1F7D-4B05-B3EB-44850177E001Q35620058-90DB3507-7EEB-4A39-93CE-833DF60A2D36Q35662646-1136C9D5-1A33-4307-9B97-6F93CE2C6330Q35665744-193D94C7-2B5F-4521-805C-C75379758E9BQ36013070-4BFD880D-2107-4ECF-87FB-5326B5C5918FQ36150572-8F4B7BB8-671D-4C34-B937-849F6498C40FQ36357886-013AEB52-B46C-43B1-AA43-E3E211E059A3Q36481525-7B4225E5-C410-49CF-A31A-2C06D2F08DD2Q36484894-67BDB01E-927F-435E-8AFB-9DFE7E3EC62FQ36500200-0EF1DB87-036E-4CD8-BBDE-C0497BE9B5DCQ36512551-64F98F56-5DBC-45D3-AD26-5C32611C3429Q36573907-EA61A36D-212F-4A32-937E-E078D1CFBF56Q36810804-3257A61F-1AFF-46A0-8F5C-07EB8BD0C18FQ36834630-8491531B-166A-4356-AE30-8102C52E346EQ36908831-AC58601A-F54D-4196-8DB4-2A1AA9911448
P2860
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@en
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@nl
type
label
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@en
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@nl
prefLabel
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@en
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@nl
P2093
P1433
P1476
Oral sildenafil is an effectiv ...... son with inhaled nitric oxide.
@en
P2093
Evangelos Michelakis
Kyoko Hashimoto
Linda Webster
Stephen Archer
Wayne Tymchak
P304
P356
10.1161/01.CIR.0000016641.12984.DC
P407
P577
2002-05-01T00:00:00Z